DUSP6 Inhibition Overcomes Neuregulin/HER3-Driven Therapy Tolerance in HER2+ Breast Cancer

Investigators presented transcriptional profiling of HER2+ breast cancer cells transitioning from dormant drug tolerant cells to re-proliferating cells under continuous HER2 inhibitor therapy. Expression of dual-specificity phosphatase DUSP6 was found inhibited in dormant cells, but strongly induced upon regrowth.